SARS-CoV-2 RBD-Tetanus Toxoid Conjugate Vaccine Induces a Strong Neutralizing Immunity in Preclinical Studies

Controlling the global COVID-19 pandemic depends, among other measures, on developing preventive vaccines at an unprecedented pace. Vaccines approved for use and those in development intend to elicit neutralizing antibodies block viral sites binding host’s cellular receptors. Virus infection is mediated by spike glycoprotein trimer virion surface via its receptor domain (RBD). Antibody response this important outcome of immunization correlates well with neutralization. Here, we show that macromolecular constructs recombinant RBD conjugated tetanus toxoid (TT) induce a potent immune laboratory animals. Some advantages RBD-TT conjugates include predominant IgG due affinity maturation long-term specific B-memory cells. These result demonstrate potential conjugate vaccine candidates enable their advance clinical evaluation under name SOBERANA02, paving way antiviral vaccines.